|
23 Companies |
|
30 Products |
|
30 Products |
|
0 Mechanisms of Action |
|
0 Trials |
|
425 News |
|
| «123456789» |
- |||| Tracleer (bosentan) / J&J, Roche
Trial completion, Trial primary completion date, Monotherapy: Compass-2: Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Jan 26, 2015
P4, N=334, Completed, Sponsor: Actelion
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Dec 2013
- | Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Enrollment open: Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years (clinicaltrials.gov) - Jan 22, 2015
P2, N=40, Recruiting, Sponsor: United Therapeutics
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Dec 2013 Not yet recruiting --> Recruiting
- Clinical: Evaluating Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis (clinicaltrials.gov) - Jan 18, 2015
P=N/A, N=20, Not yet recruiting, Sponsor: Echosense Ltd.
- Enrollment open: Evaluation of Pulmonary Doppler Signals in Patients With Systemic Sclerosis(SSc) (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=20, Recruiting, Sponsor: Echosense Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc) (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=20, Recruiting, Sponsor: Echosense Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment closed: Comparative PK PD Study in PAH Patients (Fox vs. I-Neb) (clinicaltrials.gov) - Jan 15, 2015
P1/2, N=27, Active, not recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- tacrolimus intravenous / Generic mfg.
Enrollment change, Trial termination: TransformPAH: FK506 (Tacrolimus) in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jan 7, 2015
P2, N=23, Terminated, Sponsor: Edda Spiekerkoetter
N=40 --> 23 | Recruiting --> Terminated; Prematurely stopped due to limited funding/slow patient recruitment in single academic center. Follow-up multicenter phase IIb efficacy trial is planned.
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial termination: Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease (clinicaltrials.gov) - Dec 29, 2014
P=N/A, N=5, Terminated, Sponsor: University of California, Los Angeles
Follow-up multicenter phase IIb efficacy trial is planned. Completed --> Terminated; enrollment was too slow
- treprostinil / Generic mfg.
Clinical: PKRemodulin: Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=50, Recruiting, Sponsor: Jeffrey A. Feinstein
- Enrollment change, Trial primary completion date: Inhaled Nitrite in Subjects With Pulmonary Hypertension (clinicaltrials.gov) - Dec 7, 2014
P2, N=50, Recruiting, Sponsor: University of Pittsburgh
Completed --> Terminated; enrollment was too slow N=30 --> 50 | Trial primary completion date: Oct 2014 --> Oct 2016
- ||| Clinical: LONGACT: Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=90, Not yet recruiting, Sponsor: Actelion
- |||| selonsertib (GS-4997) / Gilead
Enrollment open: ARROW: Selonsertib in Adults With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 5, 2014
P2, N=120, Recruiting, Sponsor: Gilead Sciences
N=30 --> 50 | Trial primary completion date: Oct 2014 --> Oct 2016 Not yet recruiting --> Recruiting
- Trial termination: Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003) (clinicaltrials.gov) - Dec 5, 2014
P1, N=20, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Recruiting --> Terminated
- |||||||||| Zydena (udenafil) / Mezzion
New P2/3 trial: Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH (clinicaltrials.gov) - Dec 1, 2014
P2/3, N=60, Recruiting, Sponsor: Dong-A ST Co., Ltd.
- || ranolazine ER / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Ranolazine and Pulmonary Hypertension (clinicaltrials.gov) - Nov 20, 2014
P3, N=11, Completed, Sponsor: Northwestern University
Recruiting --> Terminated Recruiting --> Completed | N=25 --> 11 | Trial primary completion date: Jun 2013 --> Jan 2014
- Trial termination: Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005) (clinicaltrials.gov) - Nov 19, 2014
P1, N=18, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | N=25 --> 11 | Trial primary completion date: Jun 2013 --> Jan 2014 Suspended --> Terminated
- Tyvaso (treprostinil) / United Therapeutics Corp
Enrollment change, Trial termination: Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching (clinicaltrials.gov) - Nov 12, 2014
P=N/A, N=9, Terminated, Sponsor: University of Florida
United Therapeutics and Dr. Bajwa MD decided to terminate study
- Tyvaso (treprostinil) / United Therapeutics Corp
Trial primary completion date: Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication (clinicaltrials.gov) - Nov 3, 2014
P4, N=21, Active, not recruiting, Sponsor: Los Angeles Biomedical Research Institute
Bajwa MD decided to terminate study Trial primary completion date: Dec 2013 --> Dec 2014
- Clinical: Evaluation of Pulmonary Doppler Signals in Patients With Systemic Sclerosis(SSc) (clinicaltrials.gov) - Oct 30, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: Echosense Ltd.
- | Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
New P2 trial: Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years (clinicaltrials.gov) - Oct 28, 2014
P2, N=40, Not yet recruiting, Sponsor: United Therapeutics
- ||||||| ambrisentan / Generic mfg.
Trial completion: Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Oct 27, 2014
P3, N=134, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2013 --> Dec 2014 Active, not recruiting --> Completed
- Biomarker: The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHD (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=100, Not yet recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- |||| Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open: Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) (clinicaltrials.gov) - Oct 15, 2014
P4, N=100, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Trial completion, Phase classification, Enrollment change: Assessmet of Patients With PAH Right Ventricular Volume (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=103, Completed, Sponsor: VentriPoint Diagnostics Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Phase classification: P3 --> PN/A | N=83 --> 103
- || imatinib / Generic mfg.
Trial completion: Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Oct 10, 2014
P3, N=17, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Phase classification: P3 --> PN/A | N=83 --> 103 Active, not recruiting --> Completed
- Trial suspension: Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005) (clinicaltrials.gov) - Oct 10, 2014
P1, N=18, Suspended, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Suspended
- ||||||| ambrisentan / Generic mfg.
Trial completion, Combination therapy: AMBITION: A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Sep 29, 2014
P3, N=610, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Suspended Active, not recruiting --> Completed
- |||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Trial primary completion date: GRIPHON: Selexipag (ACT-293987) in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Sep 28, 2014
P3, N=1156, Active, not recruiting, Sponsor: Actelion
Active, not recruiting --> Completed Trial primary completion date: Mar 2014 --> Sep 2014
- Clinical: Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc) (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: Echosense Ltd.
- Clinical: Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound (clinicaltrials.gov) - Sep 19, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: Echosense Ltd.
- Trial primary completion date: Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography (clinicaltrials.gov) - Sep 16, 2014
P=N/A, N=25, Active, not recruiting, Sponsor: Medical University of Graz
Trial primary completion date: Mar 2014 --> Sep 2014 Trial primary completion date: May 2014 --> May 2017
- Enrollment change, Trial withdrawal: (-)-Epicatechin and Pulmonary Arterial Hypertension (clinicaltrials.gov) - Sep 10, 2014
P1, N=0, Withdrawn, Sponsor: University of California, San Francisco
Trial primary completion date: May 2014 --> May 2017 N=15 --> 0 | Active, not recruiting --> Withdrawn
- ||||| selonsertib (GS-4997) / Gilead
New P2 trial: ARROW: Selonsertib in Adults With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Sep 9, 2014
P2, N=120, Not yet recruiting, Sponsor: Gilead Sciences
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion, Enrollment change, Adherence: Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=38, Completed, Sponsor: Bayer
N=15 --> 0 | Active, not recruiting --> Withdrawn Active, not recruiting --> Completed | N=50 --> 38
- New P2 trial: Safety of Terbogrel in Patients With Primary Pulmonary Hypertension (clinicaltrials.gov) - Aug 22, 2014
P2, N=33, Terminated, Sponsor: Boehringer Ingelheim
- ||||| New P2 trial: Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension (clinicaltrials.gov) - Aug 22, 2014
P2, N=71, Completed, Sponsor: Boehringer Ingelheim
- |||| Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion: An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension (clinicaltrials.gov) - Aug 21, 2014
P2, N=75, Completed, Sponsor: Bayer
Active, not recruiting --> Completed | N=50 --> 38 Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Oral Iron Supplementation in Pulmonary Hypertension (clinicaltrials.gov) - Aug 12, 2014
P=N/A, N=6, Completed, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=25 --> 6 | Trial primary completion date: Jan 2014 --> Aug 2014
- Tracleer (bosentan) / J&J, Roche
Trial completion, Enrollment change: SCOBA-PH: Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension (clinicaltrials.gov) - Aug 11, 2014
P4, N=32, Completed, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed | N=25 --> 6 | Trial primary completion date: Jan 2014 --> Aug 2014 Active, not recruiting --> Completed | N=110 --> 32
- carvedilol / Generic mfg.
Enrollment open: Carvedilol PAH A Pilot Study of Efficacy and Safety (clinicaltrials.gov) - Aug 5, 2014
P2, N=25, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed | N=110 --> 32 Not yet recruiting --> Recruiting
- Biomarker, Enrollment closed, Trial primary completion date: EFORT: Prospective Longitudinal Study of Patients With Idiopathic Pulmonary Arterial Hypertension, Family or Taking Anorectics (clinicaltrials.gov) - Jul 28, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jan 2016
- Enrollment open, FDG PET: Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI. (clinicaltrials.gov) - Jul 24, 2014
P2, N=36, Recruiting, Sponsor: Brigham and Women's Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jan 2016 Not yet recruiting --> Recruiting
- ||| ambrisentan / Generic mfg.
Enrollment closed, Trial primary completion date: ATPAHSS: A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (clinicaltrials.gov) - Jul 17, 2014
P4, N=63, Active, not recruiting, Sponsor: United Therapeutics
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Nov 2014
- ||||| Adempas (riociguat) / Bayer, Merck (MSD)
New P4 trial: Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) (clinicaltrials.gov) - Jul 16, 2014
P4, N=100, Not yet recruiting, Sponsor: Bayer
- || Tyvaso (treprostinil) / United Therapeutics Corp
Enrollment closed, Adverse events: Aspire: Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso (clinicaltrials.gov) - Jul 16, 2014
P=N/A, N=1320, Active, not recruiting, Sponsor: United Therapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- ||| Trial completion, MRI: Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=90, Completed, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Recruiting --> Completed
- treprostinil / Generic mfg.
Enrollment change: A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=13, Completed, Sponsor: United Therapeutics
Recruiting --> Completed N=20 --> 13
- | treprostinil / Generic mfg.
Trial completion, Enrollment change: A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=13, Completed, Sponsor: United Therapeutics
N=20 --> 13 Active, not recruiting --> Completed | N=20 --> 13
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment change: IBUKI: Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study (clinicaltrials.gov) - Jun 17, 2014
P3, N=27, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed | N=20 --> 13 N=20 --> 27
- ||||| ambrisentan / Generic mfg.
Enrollment closed: Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Jun 17, 2014
P3, N=120, Active, not recruiting, Sponsor: GlaxoSmithKline
N=20 --> 27 Recruiting --> Active, not recruiting